Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
300347 Hangzhou Tigermed Consulting
- 53.67
- +2.86+5.63%
Market Closed Apr 1 15:00 CST
46.42BMarket Cap114.68P/E (TTM)
54.79High50.41Low144.10KlotVolume51.21Open50.81Pre Close767.50MTurnover2.53%Turnover Ratio114.68P/E (Static)864.95MShares82.7952wk High2.25P/B30.60BFloat Cap45.8452wk Low60.97Limit Up570.14MShs Float207.81Historical High40.65Limit Down8.62%Amplitude1.04Historical Low0.57Dividend TTM53.26Avg Price56.94KlotAsk1.06%Div YieldTTM100Lot Size72.84KlotBid
Hangzhou Tigermed Consulting Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -10.58%6.6B | -10.32%5.07B | -9.50%3.36B | -8.00%1.66B | 4.21%7.38B | 4.52%5.65B | 3.25%3.71B | -0.73%1.8B | 35.91%7.09B | 59.23%5.41B |
| Operating revenue | -10.58%6.6B | -10.32%5.07B | -9.50%3.36B | -8.00%1.66B | 4.21%7.38B | 4.52%5.65B | 3.25%3.71B | -0.73%1.8B | 35.91%7.09B | 59.23%5.41B |
| Other operating revenue | 35.93%129.04M | ---- | 54.47%62.55M | ---- | 13.10%94.93M | ---- | -2.12%40.49M | ---- | 220.69%83.93M | ---- |
| Total operating cost | 1.01%5.61B | -2.79%4.03B | -3.45%2.63B | -4.04%1.31B | 7.71%5.55B | 6.96%4.14B | 4.74%2.72B | 1.54%1.36B | 41.75%5.16B | 69.35%3.87B |
| Operating cost | -3.85%4.36B | -8.12%3.1B | -9.17%2.03B | -5.23%1.03B | 6.04%4.54B | 4.12%3.37B | 2.88%2.23B | -2.06%1.09B | 45.33%4.28B | 79.13%3.24B |
| Operating tax surcharges | 0.62%28.04M | 4.43%22.39M | -2.10%14.49M | 12.42%7.7M | 21.06%27.87M | 55.09%21.44M | 73.21%14.8M | 95.71%6.85M | 2.14%23.02M | -11.98%13.82M |
| Operating expense | 10.83%207.61M | 9.22%144.94M | 13.91%101.38M | 3.43%46.45M | 24.97%187.31M | 22.94%132.7M | 11.19%89M | 16.61%44.91M | 15.84%149.89M | 12.61%107.94M |
| Administration expense | 13.33%736.84M | 5.85%558.43M | 8.70%376.62M | 3.60%177.07M | 3.18%650.2M | 14.39%527.54M | 10.46%346.47M | 7.54%170.92M | 15.10%630.13M | 18.67%461.2M |
| Financial expense | 135.14%38.07M | 129.66%31.37M | 81.71%-16.11M | -37.34%-21.92M | 31.49%-108.32M | 11.06%-105.76M | -6.04%-88.09M | 47.37%-15.96M | 26.92%-158.12M | 32.28%-118.91M |
| -Interest expense (Financial expense) | 17.80%141.24M | ---- | 27.68%67.43M | ---- | 44.14%119.9M | ---- | 70.18%52.81M | ---- | 233.92%83.18M | ---- |
| -Interest Income (Financial expense) | 60.75%-90.22M | ---- | 41.75%-71.38M | ---- | -1.10%-229.85M | ---- | -8.51%-122.54M | ---- | 11.15%-227.34M | ---- |
| Research and development | -8.86%238.39M | -11.90%172.1M | -2.65%124.69M | -0.95%63.91M | 11.48%261.56M | 14.20%195.34M | 15.89%128.08M | 13.22%64.52M | 10.76%234.62M | 10.50%171.06M |
| Credit Impairment Loss | 8.07%-35.28M | -32.34%-44.44M | -28.29%-27.66M | 30.09%-10.65M | -69.76%-38.37M | -82.27%-33.58M | -82.24%-21.56M | -192.96%-15.24M | -96.39%-22.6M | -203.43%-18.42M |
| Asset Impairment Loss | 104.22%1.25M | 9.41%-10.66M | -2.51%-8.42M | -41.16%-7.75M | -1,130.46%-29.73M | 55.75%-11.76M | 50.44%-8.22M | 15.73%-5.49M | 81.30%-2.42M | -126.73%-26.59M |
| Other net revenue | -150.02%-328.65M | -94.53%43.93M | -107.39%-44.9M | -96.10%7.28M | 0.54%657.03M | 71.84%803.43M | 25.64%607.77M | 5.94%186.62M | -69.19%653.47M | -62.07%467.53M |
| Fair value change income | -242.21%-501.69M | -104.84%-34.41M | -118.58%-98.4M | -92.77%12.75M | -34.17%352.77M | 76.46%710.39M | 28.18%529.76M | 40.98%176.41M | -70.48%535.86M | -63.97%402.59M |
| Invest income | -50.72%166.64M | -14.54%109.16M | -28.47%70.74M | -113.93%-3.59M | 229.12%338.18M | 38.14%127.74M | 14.41%98.9M | -53.59%25.78M | -67.10%102.75M | -26.13%92.47M |
| -Including: Investment income associates | -70.27%31.27M | ---- | -30.80%44.1M | ---- | 164.53%105.18M | ---- | 79.22%63.72M | ---- | 177.13%39.76M | ---- |
| Asset deal income | 1,994.43%3.56M | 5,815.94%2.67M | 25,346.07%1.49M | 32,651.46%1.15M | -117.12%-188.09K | 282.55%45.22K | 94.60%-5.9K | 41.47%-3.54K | 83.68%-86.63K | 95.63%-24.77K |
| Other revenue | 7.23%36.85M | 103.79%21.61M | 95.00%17.35M | 198.25%15.37M | -14.02%34.37M | -39.47%10.6M | -28.95%8.9M | -28.40%5.15M | 116.31%39.97M | 108.96%17.52M |
| Operating profit | -73.28%664.42M | -53.07%1.08B | -57.02%687.07M | -42.59%362.2M | -3.70%2.49B | 15.53%2.31B | 7.95%1.6B | -3.59%630.9M | -30.15%2.58B | -14.52%2B |
| Add:Non operating Income | -62.17%5.09M | -22.32%5.34M | 8.81%4.95M | -64.48%301.24K | 19.07%13.45M | -37.72%6.87M | 11.52%4.55M | -51.06%848.03K | 78.60%11.3M | 353.45%11.03M |
| Less:Non operating expense | -57.45%5.05M | -20.79%3.27M | -51.86%1.93M | -80.51%133.27K | 42.56%11.86M | -31.67%4.13M | -22.05%4M | 510.81%683.69K | -55.57%8.32M | -18.08%6.04M |
| Total profit | -73.30%664.46M | -53.03%1.09B | -56.85%690.09M | -42.58%362.36M | -3.75%2.49B | 15.38%2.31B | 8.06%1.6B | -3.80%631.06M | -29.83%2.59B | -14.12%2.01B |
| Less:Income tax cost | -36.02%216.63M | -35.83%183.93M | -30.64%132.51M | -20.63%49.79M | 7.96%338.61M | 22.61%286.62M | 17.76%191.06M | -23.52%62.74M | 7.10%313.65M | 55.66%233.77M |
| Net profit | -79.17%447.83M | -55.46%903.14M | -60.40%557.58M | -45.00%312.57M | -5.36%2.15B | 14.42%2.03B | 6.87%1.41B | -0.98%568.33M | -33.02%2.27B | -18.92%1.77B |
| Net profit from continuing operation | -79.17%447.83M | -55.46%903.14M | -60.40%557.58M | -45.00%312.57M | -5.36%2.15B | 14.42%2.03B | 6.87%1.41B | -0.98%568.33M | -33.02%2.27B | -18.92%1.77B |
| Less:Minority Profit | -65.87%42.69M | -39.49%89.71M | 227.70%64.73M | 59,975.46%77.5M | -52.83%125.08M | -11.54%148.24M | -84.28%19.75M | -100.23%-129.43K | -48.76%265.17M | -58.59%167.58M |
| Net profit of parent company owners | -79.99%405.14M | -56.72%813.43M | -64.50%492.85M | -58.65%235.07M | 0.91%2.02B | 17.13%1.88B | 16.47%1.39B | 9.65%568.46M | -30.19%2.01B | -9.90%1.6B |
| Earning per share | ||||||||||
| Basic earning per share | -79.91%0.47 | -56.68%0.94 | -64.60%0.57 | -59.09%0.27 | 0.86%2.34 | 16.67%2.17 | 16.67%1.61 | 10.00%0.66 | -29.91%2.32 | -9.27%1.86 |
| Diluted earning per share | -79.91%0.47 | -56.68%0.94 | -64.60%0.57 | -59.09%0.27 | 0.86%2.34 | 16.67%2.17 | 16.67%1.61 | 10.00%0.66 | -29.70%2.32 | -8.82%1.86 |
| Other composite income | -156.74%-30.37M | -175.72%-50.71M | -129.44%-30.37M | 52.23%-22.24M | -82.36%53.52M | -80.90%66.97M | -44.19%103.16M | -1,745.48%-46.55M | 437.31%303.3M | 1,155.99%350.58M |
| Other composite income of parent company owners | -111.69%-4.44M | -163.12%-26.16M | -117.63%-12.32M | 75.47%-7.57M | -82.86%37.98M | -84.36%41.44M | -50.80%69.87M | -5,556.32%-30.86M | 446.27%221.54M | 1,316.79%264.96M |
| Other composite income of minority owners | -266.93%-25.93M | -196.16%-24.55M | -154.22%-18.05M | 6.53%-14.67M | -81.00%15.53M | -70.18%25.53M | -22.24%33.29M | -693.80%-15.69M | 415.19%81.76M | 849.48%85.62M |
| Total composite income | -81.05%417.46M | -59.31%852.43M | -65.11%527.21M | -44.36%290.33M | -14.43%2.2B | -1.32%2.09B | 0.59%1.51B | -8.69%521.77M | -22.01%2.58B | -1.38%2.12B |
| Total composite income of parent company owners | -80.58%400.7M | -59.02%787.27M | -67.05%480.53M | -57.68%227.5M | -7.42%2.06B | 2.75%1.92B | 9.31%1.46B | 3.81%537.59M | -20.71%2.23B | 6.27%1.87B |
| Total composite income of minority owners | -88.08%16.76M | -62.51%65.15M | -12.00%46.68M | 497.08%62.83M | -59.47%140.61M | -31.37%173.78M | -68.51%53.05M | -129.53%-15.82M | -29.43%346.93M | -35.61%253.2M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.